TissueCypher Test Outperforms Standard in Predicting Barrett’s Esophagus Progression

Date:

Castle Biosciences, a leading diagnostics company, has announced the publication of data showing that its TissueCypher Barrett’s Esophagus test outperformed standard pathology review in predicting the progression of Barrett’s esophagus (BE) to more advanced stages. The study, published in Gastroenterology, evaluated the risk-stratification performance of the TissueCypher test in BE patients with an initial diagnosis of low-grade dysplasia (LGD).

Barrett’s esophagus is a condition where the lining of the esophagus becomes damaged, typically due to chronic acid reflux. It is a precursor to esophageal cancer, and accurately predicting which patients are at high risk for developing advanced forms of the disease or cancer can be challenging. The TissueCypher test, which utilizes Artificial Intelligence, provides a deeper analysis of a patient’s disease compared to traditional pathology review, offering objective information regarding the patient’s risk of progressing to esophageal cancer.

The study compared the performance of the TissueCypher test against an international panel of expert and community-based pathologists. The test demonstrated higher sensitivity in detecting patients who progressed to high-grade dysplasia (HGD) or esophageal adenocarcinoma (EAC) when compared to the panel of pathologists. Importantly, it also identified a significant number of progressors who were downstaged to non-dysplastic Barrett’s esophagus (NDBE) by the pathologists, potentially leading to missed diagnoses using standard care. When used in combination with pathology review, the TissueCypher test accurately identified a substantial majority of patients who progressed, indicating its potential for early detection.

The study further revealed that patients with NDBE who received high-risk scores from the TissueCypher test had a higher rate of progression to HGD/EAC within five years compared to patients with confirmed LGD by expert pathologists. This subset of patients, who may go undetected by standard care pathology review, can benefit from early intervention with endoscopic eradication therapy to prevent the development of esophageal adenocarcinoma.

See also  AI Answering Investing Questions: ChatGPT

The results of the study demonstrate that the TissueCypher Barrett’s Esophagus test can accurately predict the progression of low-grade dysplasia to more advanced stages. By providing an objective solution to the variability in pathology review, the test enables physicians to make more informed decisions regarding patient management, including upstaging care for high-risk patients and reducing unnecessary interventions for low-risk patients.

Castle Biosciences is focused on improving health through innovative tests that guide patient care. In addition to the TissueCypher test, the company’s portfolio includes tests for skin cancers, uveal melanoma, and mental health conditions. The company is also actively developing tests for other diseases with high clinical need.

Frequently Asked Questions (FAQs) Related to the Above News

What is Barrett's esophagus?

Barrett's esophagus is a condition where the lining of the esophagus becomes damaged, typically due to chronic acid reflux. It is a precursor to esophageal cancer.

What is the TissueCypher Barrett's Esophagus test?

The TissueCypher Barrett's Esophagus test is a diagnostic test developed by Castle Biosciences. It utilizes Artificial Intelligence to provide a deeper analysis of a patient's Barrett's esophagus, offering objective information regarding the patient's risk of progressing to esophageal cancer.

How does the TissueCypher test compare to standard pathology review?

The TissueCypher test outperformed standard pathology review in predicting the progression of Barrett's esophagus to more advanced stages. It demonstrated higher sensitivity in detecting patients who progressed to high-grade dysplasia or esophageal adenocarcinoma when compared to a panel of expert and community-based pathologists.

What are the potential benefits of the TissueCypher test?

The TissueCypher test provides physicians with more accurate information about a patient's risk of developing advanced forms of Barrett's esophagus or esophageal cancer. This enables more informed decisions regarding patient management, including upstaging care for high-risk patients and reducing unnecessary interventions for low-risk patients. Early intervention can be initiated for patients with high-risk scores, potentially preventing the development of esophageal adenocarcinoma.

Can the TissueCypher test be used in combination with standard pathology review?

Yes, the TissueCypher test can be used in combination with standard pathology review. When used together, the TissueCypher test accurately identified a substantial majority of patients who progressed, indicating its potential for early detection.

What other conditions does Castle Biosciences focus on?

In addition to the TissueCypher Barrett's Esophagus test, Castle Biosciences develops tests for skin cancers, uveal melanoma, and mental health conditions. The company is also actively developing tests for other diseases with high clinical need.

Please note that the FAQs provided on this page are based on the news article published. While we strive to provide accurate and up-to-date information, it is always recommended to consult relevant authorities or professionals before making any decisions or taking action based on the FAQs or the news article.

Share post:

Subscribe

Popular

More like this
Related

YouTubers Fear for Future as OpenAI’s Video Tool Sora Sparks Controversy

Explore how openAI's Sora is causing a stir among YouTubers, sparking debates on AI's role in the future of content creation.

Sam Altman’s Rise: Confronting Humanity’s Soul Sickness in Silicon Valley

Discover Sam Altman's journey in confronting humanity's soul sickness in Silicon Valley. Learn the main points of this thought-provoking article here.

Super Micro Computer (SMCI) Stock Forecast: AI Predicts Continued Growth in 2024

Super Micro Computer (SMCI) stock forecast: AI predicts continued growth in 2024, despite recent market challenges.

OpenAI’s ChatGPT Losing Its Mind: Users Share Bizarre Interactions

Users share bizarre interactions with OpenAI's ChatGPT as the chatbot goes haywire, leaving them baffled by its nonsensical responses.